Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Juliana Velez Lujan, BS,PhD, Michael Y. Choi, MD, Chaja Jacobs, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD

Blood (2018) 132 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2018-99-118990

Published: 2018

Journal Articles

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Juliana Velez Lujan, BS,PhD, Chaja Jacobs, MD, Paula A Lengerke Diaz, MD, Eider F Moreno-Cortes, MD, Cesar A Ramirez-Segura, BS, PhD, Michael Y. Choi, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD

Blood (2018) 132 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2018-99-119523

Published: 2018